SKILLMAN, N.J., March 12, 2025 — Kenvue Inc. (NYSE: KVUE) is sharing 12 new scientific studies showcasing advancements in oral care at the 2025 AADOCR/CADR Annual Meeting & Exhibition, March 12-15 in New York, N.Y. The studies add to the body of scientific data showing positive clinical outcomes of LISTERINE® use as part of daily oral hygiene for a wide range of patients, including patients diagnosed with diabetes. Kenvue will also host a Scientific Symposium, where field-leading experts will explore the link between oral inflammation and systemic health.
An oral presentation will be shared during the “Oral Hygiene Device Efficacy” session, held on Wednesday, March 12 from 1:30-3pm ET. Highlights include 12-week clinical trial outcomes which could be highly relevant to millions of patients living with types 1 and 2 diabetes. This is the first study to evaluate the efficacy and safety of LISTERINE® use in patients diagnosed with diabetes. Outcomes demonstrate that daily LISTERINE® use (both alcohol-free and alcohol-containing formulas) resulted in statistically significant reductions in plaque and gingivitis compared to the comparator study group (negative control rinse). Both LISTERINE® formulations were well-tolerated by diabetic patients and within the established safety profile.
“Our researchers will showcase a multitude of new information including the effect of low-pH anticavity and cosmetic mouthrinses on salivary flow,” said Karina Ribeiro, Global Head of R&D, Essential Health at Kenvue. “From new science on fluoride, to data on essential oil mouthrinses and the overall impact of mouthrinses in various demographics, this work speaks to our goal of continually advancing the science of oral care through iconic brands like LISTERINE®, helping doctors and patients improve oral and systemic health.”
Eleven additional poster abstracts will be available in Hall 3 of the Javits Center for the duration of the meeting. One study showcases the first trial outcomes in subjects 55 years of age or older. Daily LISTERINE® use showed statistically significant reductions of clinical signs of plaque and gingivitis compared to brushing alone. Researchers also studied the treatment of dentinal hypersensitivity in a randomized, controlled clinical trial. Potassium oxalate mouth rinse was shown to significantly reduce dentinal hypersensitivity in subjects with sensitivity compared to the negative control group as early as day five through week four. And, new data from an international survey showed gaps in knowledge of the oral microbiome, pointing to a global need for more education on this topic.
The company will hold a Scientific Symposium, “Where does prevention fit in? Unraveling the link between oral inflammation and systemic health” on Wednesday, March 12 from 12:15 – 1:30 p.m. in Room 1A23. Kimberly Milleman, RDH, PhD, Global Clinical Director at Salus Research, Maria L. Geisinger, DDS, University of Alabama Professor and Periodontology Chair, and Michael Glogauer, DDS, PhD, Professor at University of Toronto, Dentist-in-Chief at University Health Network, and Head of Dental Oncology at Princess Margaret Cancer Centre, will all present their latest research findings on the link between oral and systemic inflammation, and lead a discussion on the topic of periodontal disease prevention.
To learn more about these results or interview authors, please contact R&D media relations or visit Kenvue booth #107 during the conference.
About Kenvue
Kenvue Inc. is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.
About Listerine®
Listerine® is a brand of Kenvue Brands LLC, a subsidiary of Kenvue Brands LLC.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding Listerine® and oral health research. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates.
A list and descriptions of risks, uncertainties and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.
Contact
R&D Media Relations
Meghan Harding
MHardin1@kenvue.com